未名醫藥(002581.SZ):擬簽署《藥物臨牀試驗技術服務協議》
格隆匯1月3日丨未名醫藥(002581.SZ)公佈,全資子公司山東衍渡生物科技有限公司(簡稱“山東衍渡”)就擬開展的重組人神經生長因子滴眼液III期臨牀試驗研究與天津開心生活科技有限公司(簡稱“開心生活”)簽署《藥物臨牀試驗技術服務協議》,聘請開心生活提供臨牀試驗技術服務。
III期臨牀試驗是新藥研發過程中至關重要的一步,其時間節點直接影響藥品上市的週期。公司本次擬開展重組人神經生長因子滴眼液III期臨牀試驗研究,並就該事項擬與開心生活簽署《技術服務協議》,聘請開心生活為III期臨牀試驗事項提供臨牀試驗技術服務,有利於雙方充分發揮各自的資源和優勢,共同推進臨牀試驗的各項工作,確保臨牀試驗高效、有序開展,從而縮短整體研發週期,加速新藥的上市進程,有效提升公司在臨牀試驗及新藥研發方面的整體競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.